课题基金 / 基金详情

THE OUTER MEMBRANE AS A VIRULENCE PLATFORM

THE OUTER MEMBRANE AS A VIRULENCE PLATFORM
外膜作为毒力平台
批准号:
8105432
负责人:
DAVID ALAN HUNSTAD
金额:
$29.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-17 至 2014-06-30

项目摘要

项目成果

DAVID ALAN HUNSTAD的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):革兰氏阴性致病菌的外膜(OM)是表面定位毒力因子分泌和呈现的平台。保守的质周伴侣蛋白SurA将新生的OM蛋白从Sec机制运送到BamA OM组装复合体,并最终整合到OM中。我们的原始工作证明了SurA在尿路致病性大肠杆菌(UPEC)引起的尿路感染发病机制中的重要性。UPEC中surA的破坏导致OM usher find的缺乏,细菌细胞通过它组装粘附的1型菌毛,使UPEC具有结合和侵袭膀胱上皮的能力。我们还发现,SurA底物在膀胱炎侵袭后阶段具有额外的作用,在此阶段,UPEC在膀胱上皮细胞内迅速繁殖,形成细胞内细菌群落(IBCs),并在上皮内建立持久的生态位,与宿主免疫防御隔离,免受抗生素杀伤。这种上皮内细菌储存库可作为复发性尿路感染的种子,这是一个常见而困难的临床问题。我们最近的数据已经确定UPEC外膜蛋白A (OmpA)是膀胱炎细胞内期所需的苏拉依赖因子。具体来说,UPEC ompA突变体正常侵入膀胱上皮,但不能完成IBC成熟并在尿上皮内持续存在。在toll样受体4信号缺失的小鼠中,这种致病性缺陷基本上得到了修复,这表明OmpA调节宿主免疫机制以促进感染。在本提案中,我们将首先定义OmpA对宿主先天反应(包括中性粒细胞募集和膀胱上皮脱落)和适应性反应的贡献。我们随后将解决OmpA是否对中性粒细胞的抗病原体活性,特别是先天抗菌肽的作用具有保护作用。最后,我们将使用染色体互补系统来确定我们观察到的致病表型的OmpA的结构特征。我们预计这些研究将验证SurA底物OmpA作为膀胱炎细胞内期的中心决定因素,并为阻断尿路感染患者复发周期的策略发展提供信息。公共卫生相关性:许多细菌表达表面蛋白(称为毒力因子),帮助细菌引起人类传染病。该项目旨在确定这些细菌表面蛋白中的一种,称为OmpA,如何与人体免疫系统相互作用,促进尿路感染的建立。了解OmpA的功能将为预防和治疗细菌感染提供新的策略。
英文摘要
DESCRIPTION (provided by applicant): The outer membrane (OM) of Gram-negative pathogenic bacteria represents a platform for the secretion and presentation of surface-localized virulence factors. The conserved periplasmic chaperone SurA ferries nascent OM proteins from the Sec machinery to the BamA OM assembly complex for their final incorporation into the OM. Our original work demonstrated the importance of SurA in the pathogenesis of urinary tract infections caused by uropathogenic Escherichia coli (UPEC). Disruption of surA in UPEC leads to deficiency of the OM usher FimD, through which the bacterial cell assembles the adhesive type 1 pili that confer upon UPEC the capacity for bladder epithelial binding and invasion. We also showed that SurA substrates have an additional role during the post-invasion phase of cystitis, in which UPEC multiply rapidly within bladder epithelial cells to form intracellular bacterial communities (IBCs) and establish a persistent niche within the epithelium, sequestered from host immune defenses and protected from antibiotic killing. This intraepithelial bacterial reservoir may serve as a seed for recurrent UTI, a common and difficult clinical problem. Our recent data have identified the UPEC outer membrane protein A (OmpA) as the SurA-dependent factor required for this intracellular phase of cystitis. Specifically, the UPEC ompA mutant invades bladder epithelium normally, but cannot complete IBC maturation and persist within the uroepithelium. This pathogenic defect is substantially rescued in mice deficient in Toll-like receptor 4 signaling, suggesting that OmpA modulates host immune mechanisms to promote infection. In this proposal, we will first define the contribution of OmpA to host innate responses (including neutrophil recruitment and bladder epithelial exfoliation) and to adaptive responses. We will subsequently resolve whether OmpA confers protection against the antipathogen activity of neutrophils, particularly the action of innate antimicrobial peptides. Finally, we will use a chromosomal complementation system to determine the structural features of OmpA responsible for the pathogenic phenotypes we have observed. We anticipate that these studies will validate the SurA substrate OmpA as a central determinant of the intracellular phase of cystitis and inform the development of strategies for interrupting the cycle of recurrence in patients with UTI. PUBLIC HEALTH RELEVANCE: Many bacteria express surface proteins (called virulence factors) that help the bacteria to cause infectious diseases in humans. This project aims to determine how one of these bacterial surface proteins, called OmpA, interacts with the human immune system to facilitate the establishment of urinary tract infections. Understanding the functions of OmpA will lead to new strategies for preventing and treating bacterial infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Type 1 Pilus Receptors in Pyelonephritis and Recurrent UTI
  • 批准号:
    10378625
  • 项目类别:
  • 资助金额:
    $39.38万
  • 财政年份:
    2021
  • 负责人:
    DAVID ALAN HUNSTAD
  • 依托单位:
Novel Type 1 Pilus Receptors in Pyelonephritis and Recurrent UTI
  • 批准号:
    10594971
  • 项目类别:
  • 资助金额:
    $39.38万
  • 财政年份:
    2021
  • 负责人:
    DAVID ALAN HUNSTAD
  • 依托单位:
Novel Type 1 Pilus Receptors in Pyelonephritis and Recurrent UTI
  • 批准号:
    10180267
  • 项目类别:
  • 资助金额:
    $39.38万
  • 财政年份:
    2021
  • 负责人:
    DAVID ALAN HUNSTAD
  • 依托单位:
ANDROGEN INFLUENCE ON UTI SUSCEPTIBILITY AND SEVERITY
  • 批准号:
    9445746
  • 项目类别:
  • 资助金额:
    $34.99万
  • 财政年份:
    2018
  • 负责人:
    DAVID ALAN HUNSTAD
  • 依托单位:
海外基金